Overview of osteo-articular involvement in systemic sclerosis: Specific risk factors, clinico-sonographic evaluation, and comparison with healthy women from the French OFELY cohort

Thietart, Sara; Louati, Karine; Gatfossé, M.; Sornay‐Rendu, Elisabeth; Gaigneux, Emeline; Lemeunier, Lucie; Delmaire, P.; Rivière, Sébastien; Mahévas, Thibault; Sellam, Jérémie; Bérenbaum, Francis; Fain, Olivier; Chapurlat, Roland; Mékinian, A.

doi:10.1016/j.berh.2019.01.008

Cited by 16 publications

(17 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Настоящее исследование продемонстрировало зависимость между длительностью приема ИПП и МПК в ШБ, что расходится с данными более ранних работ, проведенных на выборках пациентов с ССД [10,11]. Однако в работах, выполненных на выборках пациентов без ревматических заболеваний, получены данные о связи приема ИПП с величиной МПК и риском остеопоротических переломов.…”

Section: Discussionunclassified

“…В работе S. Thietart и соавт. [10] клиренс креатинина в группе пациентов с ССД, имеющих ОП, был статистически значимо ниже, чем при отсутствии ОП.…”

Section: Discussionunclassified

“…[15] ИПЛ с ЛАГ выделено как фактор риска, оказывающий отрицательное влияние на величину МПК у пациентов с ССД, а в исследовании S. Thietart и соавт. [10] ДСЛ была статистически значимо ниже в группе больных ССД с ОП. При проведении корреляционного анализа нами выявлены слабые корреляционные связи между наличием нарушения ритма сердца и МПК в ШБ, снижением ДСЛ и МПК ШБ и ПОБ.…”

Section: Discussionunclassified

“…В более позднем проспективном исследовании S. Thietart и соавт. [10] оценивались как традиционные, так и связанные с заболеванием факторы риска ОП. Авторы не выявили связи таких факторов, как возраст, курение, личный или семейный анамнез переломов, употребление алкоголя, вес, ИМТ, длительное лечение глюкокортикоидами (ГК), ранняя менопауза и заболевания щитовидной железы с развитием ОП у больных ССД.…”

unclassified

“…Не было обнаружено существенных различий по кожному счету Роднана, подтипу и продолжительности ССД, наличию кальциноза, мальабсорбции, приему ингибиторов протонной помпы (ИПП), циклофосфамида и ГК, а также профилю аутоантител между пациентами с ОП и без него. Однако между ними отмечались статистически значимые различия по частоте суб-окклюзии кишечника, показателям диффузионной способности легких (ДСЛ) и форсированной жизненной емкости легких (ФЖЕЛ), DAS28-СРБ, частоте выявления эрозий в мелких суставах кистей и клиренсу креатинина [10]. Кроме того, авторы показали, что больные ССД имеют статистически значимо более низкую МПК в области проксимального отдела бедра (ПОБ) по сравнению с популяционным контролем, в то время как МПК позвоночника была сопоставимой в этих двух группах.…”

unclassified

See 4 more Smart Citations

Risk factors for low bone mineral density in postmenopausal women with systemic sclerosis

Efremova¹,

Торопцова²,

Dobrovolskaya³

et al. 2021

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Aim of the research – to determine the frequency of osteoporosis (OP) and to identify risk factors for a decrease in bone mineral density (BMD) in postmenopausal women with systemic sclerosis (SSс).Subjects and methods. The study included 113 postmenopausal women (median age – 60.0 [54.0; 63.0] years) with a reliable diagnosis of SSc according to the ACR/EULAR criteria (2013). The exclusion criterion was the presence of overlap syndromes. All women were interviewed according to a unified questionnaire, a laboratory and instrumental examination was conducted, including Dual-energy X-ray absorptiometry.Results. OP and osteopenia in at least one measurement area were diagnosed in 45.1% and 48.7% of women, respectively. Multivariate linear regression analysis revealed a negative effect of the total experience of taking glucocorticoids (GCs) on the value of BMD in the lumbar spine (b=–0.005; R2=0.136; p=0.017). Body mass index (BMI) (b=0.007; R2=0.208; p<0.001), glomerular filtration rate (GFR) (b=0.313; R2=0.213; p<0.001) is positive, and the cumulative dose of GCs (b=–0.269; R2=0.134; p<0.001), the duration of taking proton pump inhibitors (PPI) (b=–0.277; R2=0.291; p<0.001) and the duration of postmenopause (b=–0,223; R2=0.134; p<0.001) negatively affected the BMD of the femoral neck. BMD in the total hip (TH) was generally positively associated with BMI (b=0.493; R2=0.244; p<0.001), GFR (b=0.313; R2=0.150; p<0.001), 25-hydroxy calciferol level (b=0.273; R2=0.284; p=0.001), and negatively – with the cumulative dose of GCs (b=–0.219; R2=0.289; p<0.001).Conclusion. 93.8% of postmenopausal women with SSс had reduced BMD. Of the traditional risk factors, only BMI, the duration of postmenopause and the level of vitamin D had an impact on the state of BMD, and among the specific ones – the cumulative dose and duration of taking GCs, PPI and GFR.

show abstract

Section: Discussionunclassified

unclassified

See 3 more Smart Citations

Risk factors for low bone mineral density in postmenopausal women with systemic sclerosis

Efremova¹,

Торопцова²,

Dobrovolskaya³

et al. 2021

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates

Prajjwal,

Marsool,

Yadav

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundScleroderma, also referred to as systemic sclerosis, is a multifaceted autoimmune condition characterized by abnormal fibrosis and impaired vascular function. Pathologically, it encompasses the persistent presence of inflammation, abnormal collagen buildup, and restructuring of blood vessels in various organs, resulting in a wide range of clinical symptoms. This review incorporates the most recent scientific literature on scleroderma, with a particular emphasis on its pathophysiology, clinical manifestations, diagnostic approaches, and treatment options.MethodologyA comprehensive investigation was carried out on numerous databases, such as PubMed, MEDLINE, Scopus, Web of Science, and Google Scholar, to collect pertinent studies covering diverse facets of scleroderma research.ResultsScleroderma presents with a range of systemic manifestations, such as interstitial lung disease, gastrointestinal dysmotility, Raynaud's phenomenon, pulmonary arterial hypertension, renal complications, neurological symptoms, and cardiac abnormalities. Serological markers, such as antinuclear antibodies, anti‐centromere antibodies, and anti‐topoisomerase antibodies, are important for classifying diseases and predicting their outcomes.DiscussionThe precise identification of scleroderma is crucial for promptly and correctly implementing effective treatment plans. Treatment approaches aim to improve symptoms, reduce complications, and slow down the progression of the disease. An integrated approach that combines pharmacological agents, including immunosuppressants, endothelin receptor antagonists, and prostanoids, with nonpharmacological interventions such as physical and occupational therapy is essential for maximizing patient care.ConclusionThrough the clarification of existing gaps in knowledge and identification of emerging trends, our goal is to improve the accuracy of diagnosis, enhance the effectiveness of therapeutic interventions, and ultimately enhance the overall quality of life for individuals suffering from scleroderma. Ongoing cooperation and creative research are necessary to advance the field and achieve improved patient outcomes and new therapeutic discoveries.

show abstract

Body composition and bone status in relation to microvascular damage in systemic sclerosis patients

Paolino

Gotelli

Goegan

et al. 2020

J Endocrinol Invest

View full text Add to dashboard Cite

Your article is protected by copyright and all rights are held exclusively by Italian Society of Endocrinology (SIE). This e-offprint is for personal use only and shall not be selfarchived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

show abstract

Overview of osteo-articular involvement in systemic sclerosis: Specific risk factors, clinico-sonographic evaluation, and comparison with healthy women from the French OFELY cohort

Cited by 16 publications

References 41 publications

Risk factors for low bone mineral density in postmenopausal women with systemic sclerosis

Risk factors for low bone mineral density in postmenopausal women with systemic sclerosis

Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates

Body composition and bone status in relation to microvascular damage in systemic sclerosis patients

Contact Info

Product

Resources

About